December 2005

Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis

Author Affiliations

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(12):1607-1610. doi:10.1001/archderm.141.12.1607

Severe erythrodermic psoriasis, unresponsive to systemic treatments, is disabling for the patient and a challenge for dermatologists. Methotrexate, cyclosporine, and acitretin have been the treatments of choice.1 However, long-term therapy with these drugs often leads to difficult complications or adverse effects. Thus, new biologic agents such as tumor necrosis factor (TNF) inhibitors provide a welcome alternative. In controlled clinical trials, infliximab has proven to be an effective and fast-acting treatment for plaque-type psoriasis.24

First Page Preview View Large
First page PDF preview
First page PDF preview